Skip to content

Inflammation in Acute Cardiovascular Diseases - the CArdiovascular Inflammation Registry (CAIR)

An Observational-based Registry of Routinely Collected Clinical Parameters to Study Inflammation in Acute Cardiovascular Diseases - the CArdiovascular Inflammation Registry

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06411340
Acronym
CAIR
Enrollment
1000
Registered
2024-05-13
Start date
2024-07-31
Completion date
2039-07-31
Last updated
2024-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Heart Diseases, Heart Failure, Inflammation, Myocardial Infarction, Myocarditis, Pericarditis

Keywords

Inflammation, Acute cardiovascular disease, Myocarditis, Registry, Electronic health records, Pericarditis, Myocardial infarction

Brief summary

Following acute cardiovascular injury, inflammation is vital to activate reparative mechanisms. However, there is compelling evidence implicating excessive inflammation and dysregulated resolution in fibrosis, ventricular remodelling, and heart failure (HF). Recently, the anti-inflammatory agent colchicine reduced cardiovascular events after myocardial infarction (MI) compared to placebo, indicating that targeting inflammation in acute cardiovascular conditions is feasible. Several acute cardiovascular conditions are characterised by inflammation, including myocarditis, MI, and acute heart failure. However, there is large variability in definition, epidemiology, clinical presentation, pathophysiology, and natural history of acute inflammatory cardiovascular diseases. This relates, in part, to the difficulty in performing adequately powered studies. Clinical studies that include sufficient patients and extended observation periods are necessary to address some of these knowledge gaps. This registry aims to collate routinely collected clinical data on patients with acute cardiovascular diseases characterised by inflammation in an observational-based registry. By doing so, the investigators hope to understand the contribution of inflammation to the pathophysiology of acute cardiovascular disease, improve risk stratification, and identify potential novel therapeutic targets.

Interventions

OTHERObservation

Observation

Sponsors

King's College London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patient 13 years of age or older with an acute cardiovascular condition requiring hospital admission is eligible.

Exclusion criteria

* \<13 years of age

Design outcomes

Primary

MeasureTime frameDescription
All-cause mortality1 yearPrimary outcome will include all-cause mortality, but will vary by specific research project conducted within the registry.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026